Ulcerative colitis (UC) is one of the two major types of chronic inflammatory bowel diseases (IBD), along with Crohn’s disease. UC affects the large bowel, has no known cure, and requires lifelong ...

for treating adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine. The ANTHEM-UC study, conducted by Protagonist's partner, Johnson & Johnson ...

Ulcerative colitis is a chronic ... in the majority of cases. Surgery is unavoidable in some cases, but is the treatment of choice in others. While ileal pouch–anal anastomosis offers the ...

Johnson & Johnson (NYSE:JNJ) said on Monday that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative colitis, met the main goal. JNJ stock up about 1% in ...

Although uncommon, ulcerative colitis (UC ... are most common in those who’ve had ileoanal pouch anastomosis. This is a type of surgery that involves removing the large intestine and replacing ...

Removing part of the colon does not cure the disease. Ulcerative colitis may reappear in the part of the colon left after surgery. In some circumstances, your doctor may recommend removing all of ...

Daniela Soto, 25, lives in Los Angeles and was diagnosed with ulcerative colitis (UC) when she was just 21. If you don’t know much about this inflammatory bowel disease, it’s caused by an ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya (guselkumab) in ulcerative colitis (UC). The phase 3 ASTRO trial has been ...

Johnson & Johnson (J&J) announced data from the phase 3 ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at ...